April 13, 2023
Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference
April 6, 2023
Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
March 7, 2023
Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
March 2, 2023
Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock
March 1, 2023
Revolution Medicines Announces Commencement of Public Offering of Common Stock
February 27, 2023
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
February 21, 2023
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
February 2, 2023
Revolution Medicines to Participate in Upcoming Investor Conferences
January 3, 2023
Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
December 19, 2022
Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor